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Abstract
Background: Long-term exposure to anti-tuberculosis medication increases risk of adverse drug reactions and toxicity. The
objective of this investigation was to determine factors associated with anti-tuberculosis adverse drug reactions in Lima,
Peru, with special emphasis on MDR-TB medication, HIV infection, diabetes, age and tobacco use.
Methodology and Results: A case-control study was performed using information from Peruvian TB Programme. A case
was defined as having reported an anti-TB adverse drug reaction during 2005–2010 with appropriate notification on clinical
records. Controls were defined as not having reported a side effect, receiving anti-TB therapy during the same time that the
case had appeared. Crude, and age- and sex-adjusted models were calculated using odds ratios (OR) and 95% confidence
intervals (95%CI). A multivariable model was created to look for independent factors associated with side effect from anti-TB
therapy. A total of 720 patients (144 cases and 576 controls) were analyzed. In our multivariable model, age, especially those
over 40 years (OR=3.93; 95%CI: 1.65–9.35), overweight/obesity (OR=2.13; 95%CI: 1.17–3.89), anemia (OR=2.10; IC95%:
1.13–3.92), MDR-TB medication (OR=11.1; 95%CI: 6.29–19.6), and smoking (OR=2.00; 95%CI: 1.03–3.87) were
independently associated with adverse drug reactions.
Conclusions: Old age, anemia, MDR-TB medication, overweight/obesity status, and smoking history are independent risk
factors associated with anti-tuberculosis adverse drug reactions. Patients with these risk factors should be monitored during
the anti-TB therapy. A comprehensive clinical history and additional medical exams, including hematocrit and HIV-ELISA,
might be useful to identify these patients.
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Introduction
Tuberculosis (TB) is considered a ‘‘global emergency’’ by the World
Health Organization (WHO) [1]. Worldwide, about 9.4 million new
cases are diagnosed annually and 1.7 million people die due to the
infection. Moreover, over a third of the population has a latent
infection with possibility of a posterior reactivation. Recently, 440,000
cases of multidrug resistant TB (MDR-TB) have been reported [1].
In Peru, around 35,000 cases of active TB are diagnosed every
year, with morbidity and incidence rates of 118 and 103 per
100,000 people, respectively [2]. MDR-TB cases represent 5.3%
of the total cases, and about 200 cases of extremely drug-resistant
TB (XDR TB) have been reported [3,4].
Usual treatment, according to the Peruvian National Health
Strategy for Control and Prevention of Tuberculosis, is based upon
DOTS strategy [2,5]. The anti-TB therapy includes a long-time, wide
spectrum of drugs depending on the characteristics of the TB infection:
new cases, re-infection, relapses, failures, MDR-TB, or XDR-TB.
Overall, this situation can predispose patients to develop adverse drug
reactions due to the long-time exposition to the anti-TB drugs [6,7].
Anti-TB drug side effects are an inherent risk for patients
commencing any type of anti-TB therapy, especially the drug-
resistant cases. The Peruvian Ministry of Health has notified a
side-effects prevalence of 3.3% amongst treated patients [3]. The
emergence of side effects may depend on patients’ characteristics
but also on concomitant events during therapy [8], which might
determine adherence and, therefore, therapy success. Thus, an
appropriate determination of risk factors associated with anti-TB
medication adverse reaction is needed. The objective of this study
was to assess factors associated with tuberculosis treatment side
effects in Lima, Peru, with special emphasis on MDR-TB
medication, HIV infection, diabetes, age, and tobacco use,
adjusting for potential confounders.
Methods
Study Design, Setting and Participants
A retrospective, case-control study was performed using
information from the National Health Strategy for Control and
Prevention of Tuberculosis in Lima, Peru. This research used
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data as recorded from the National Strategy for Prevention and
Control of Tuberculosis at the San Juan de Miraflores-Villa Maria
del Triunfo Health Network, periurban districts located at the
south of Lima.
Those patients who had completed anti-TB treatment for
pulmonary tuberculosis in any health facility of one of the districts
aforementioned during 2005–2010 were considered for this
investigation. Patients with XDR-TB were excluded from analysis
due to their high probability of adverse effects and the
individualization of treatment schemes. Patients with extra-
pulmonary TB were also excluded from analysis because overall
it is not possible to confirm the diagnosis (bacterial and
histopathological confirmation), as well as the use of non-TB
drugs such as corticoids during the active disease.
Variable Definition
An adverse reaction was defined as having a harmful and non-
intentioned effect due to anti-TB drug administration at an
appropriate dose, being reported in clinical records with the
respective notification documentation [2].
In the same way, according to clinical records and TB
Programme information [3], the following data was extracted for
analysis—all at the beginning of their respective anti-tuberculosis
treatment: MDR-TB medication (yes/no), HIV infection (yes/no),
diabetes (yes/no), and current smoking status (yes/no). Other
variables included were: anemia (yes/no), defined using hemoglo-
bin levels (,13.0 mg/dL in men and ,12.0 mg/dL in women)
[9]; current alcohol use (yes/no); and body mass index (BMI), in
kg/m
2, defined as normal (18.5#BMI,25), overweight/obese
(BMI$25), and underweight (BMI,18.5) [10].
Cases and Control Definition
A case wasdefinedashaving reported anyTB-drug adverseeffect
(mild, moderate or severe) during 2005–2010 with the appropriate
adverse effect notification and clinical record, both part of the TB
Programme report. They must have included at least two more
variables of interest, not including sex. A control was defined as
those not having reported a side effect, receiving anti-TB therapy
duringthe sametime that the case had appeared. Thus, when a case
was found, the next 4 controls sequentially commencing treatment
at the same time were selected from the TB Programme records.
Procedures and Data Collection
Routinely, during anti-TB therapy, patients are closely
supervised until completion. When any adverse reaction emerges,
health workers should immediately report it in clinical records
using the appropriate TB Programme formats—as according to
the Peruvian National Health Strategy for Prevention and Control
of Tuberculosis and the Peruvian Ministry of Health [2]. Data was
collected directly from the clinical records and TB Programme
formats in the health facilities involved in the study. In the case of
hemoglobin levels, data was obtained from the Nutritional
Evaluation requested to all TB patients in accordance to the
Peruvian Health Ministry Protocol. This information, however,
was available only for patients who were explicitly dosed for
hemoglobin levels based upon the nutritionist criteria (about 70%
of the total) [2]. No personal identifiers were recorded to maintain
anonymity and confidentiality of the patients.
Sample Size and Statistical Analysis
Sample size was determined by including 144 cases, patients
with anti-TB treatment side effects, and 576 controls (ratio 1:4)
during the period of the study, with a power of 80% to detect an
odds ratio of 3.2 or more at the 5% level of statistical significance,
assuming exposures of 3% or greater. Thus, a total of 720 patients
were including in this study.
Data was analyzed using STATA version 11.0 for Windows
(STATA Corporation, College Station, Texas, US). First, a brief
description of demographic and clinical characteristics of the
population was tabulated. Second, association between categorical
variables and TB-drug adverse effects was assessed individually
using Chi squared (x
2) and Fisher’s exact test accordingly.
Strength of the association was calculated using logistic regression
analysis. Crude, and age- and sex-adjusted models were calculated
using odds ratios (OR) and 95% confidence intervals (95%CI).
Variables with p,0.15 in the bivariate model were used to create
a final multivariable model using a stepwise forward selection
method to look for independent factors associated with side effect
due to anti-tuberculosis therapy.
Ethics
This research proposal was approved by the School of
Medicine, Faculty of Health Sciences, of the Universidad Peruana
de Ciencias Aplicadas, Lima, Peru, as well as the Ethics
Committee of the Epidemiology Division in the National Health
Directorate II (DISA II), part of the Ministry of Health (Figure S1).
No personal identifiers were recorded to maintain anonymity and
confidentiality in this study. Informed consent was waived by IRB
because of the use of routine and programmatic data of the
National Health Strategy for Control and Prevention of
Tuberculosis.
Results
A total of 720 (144 cases and 576 controls, ratio 1:4) were
included in the study. Of them, 62.2% were males with an age
mean of 31.8 (SD: 14.5; range: 3–84) years. See Table 1.
Factors associated with anti-TB drug adverse effects after
adjusting for age, sex and year of diagnosis were: alcohol use
(p=0.009), anemia (p=0.001), overweight/obese condition
(p=0.03), HIV infection (p=0.002), and MDR-TB infection
(p,0.001). See Table 2.
When logistic regression model was used to assess independent
factors, only anemia (p=0.01), age (p=0.008), body mass index
Table 1. Characteristics of the Population.
n=720 %
Sex
Male 446 62.2%
Female 272 37.8%
Age
Mean (SD
{) 31.8 (614.5)
Year of Diagnosis
2005 52 7.8%
2006 100 15.0%
2007 122 18.3%
2008 183 27.4%
2009 152 22.8%
2010 58 8.7%
{SD: Standard deviation.
doi:10.1371/journal.pone.0027610.t001
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associated with TB drugs adverse effects. See Table 3.
Discussion
In this case-control study, age, anemia, drugs associated to
MDR-TB treatment, overweight/obesity, and smoking were
independently associated with adverse reactions from anti-
tuberculosis treatment. On the other hand, although not
significant in multivariable model, alcohol use, and HIV infection
were only associated after adjusting for age, sex and year of
diagnosis.
According to our findings, there is an increasing risk of TB-drug
adverse events when age increases. In previous reports, the
occurrence of any major side effect has been associated with age,
especially amongst the elderly [7,11]. The frequency of adverse
reactions has shown to increase in a progressive and direct form in
relationship to age [7,11]. Overall, vulnerability to adverse
reactions are more probable at older ages—especially at a
hepatotoxic level—due to a significant reduction in clearance rate
of metabolized drug agents by the cytochrome P450 enzyme,
changes in the hepatic blood flow distribution, as well as other
factors affecting liver function [12,13].
Anemia, a blood marker commonly related to chronic diseases
[14], was another factor found in our independent multivariable
model as well as in our age and sex-adjusted model. Although data
on hemoglobin levels is not routinely recommended in the
laboratory examination according to the International Standard
for Tuberculosis Care (ISTC) [15], such assessment is sometimes
required in the Peruvian context due to the multilevel evaluation
made to all TB patients including a complete nutritional
evaluation and follow-up [2]. Some studies qualify anemia and
malnutrition as risk factors for the development of anti-
tuberculosis drug adverse reactions [16,17]. Some additional
nutrition factors have been associated such as mid-arm circum-
ference and hypoalbuminaemia [18]. Thus, it is not surprising that
Table 2. Factors Associated with TB-Treatment Adverse Effects.
Variable Cases Controls p value Crude Model Adjusted Model
*
n (%) n (%) OR (95%CI) OR (95%CI)
Sex
Female 55 (38.2) 217 (37.7) 0.91 1 –
Male 89 (61.8) 359 (62.3) 0.98 (0.67–1.42) –
Age
,20 years 19 (13.2) 142 (24.7) 0.003 1 –
20–39 years 77 (53.5) 303 (52.6) 1.90 (1.11–3.26) –
40+ years 48 (33.3) 131 (22.7) 2.74 (1.53–4.90) –
Alcohol Use
No 90 (64.3) 428 (75.5) 0.007 1 1
Yes 50 (35.7) 139 (24.5) 1.71 (1.15–2.54) 1.80 (1.16–2.80)
Anemia
No 82 (69.5) 323 (81.4) 0.006 1 1
Yes 36 (30.5) 74 (18.6) 1.92 (1.20–3.05) 2.29 (1.37–3.83)
Body Mass Index
Normal 69 (57.5) 319 (69.7) 0.02 1 1
BMI$25 kg/m
2 37 (30.8) 89 (19.4) 1.92 (1.21–3.05) 1.72 (1.04–2.84)
BMI,18.5 kg/m
2 14 (11.7) 50 (10.9) 1.29 (0.68–2.47) 1.35 (0.68–2.68)
Diabetes Mellitus
{{
No 126 (92.7) 526 (96.7) 0.05 1 1
Yes 10 (7.4) 18 (3.3) 2.32 (1.05–5.15) 1.33 (0.54–3. 24)
HIV Infection
{{
No 124 (89.2) 545 (97.0) ,0.001 1 1
Yes 15 (10.8) 17 (3.0) 3.88 (1.89–7.98) 3.45 (1.61–7.45)
MDR-TB
No 74 (51.4) 529 (91.8) ,0.001 1 1
Yes 70 (48.6) 47 (8.2) 10.7 (6.84–16.6) 10.3 (6.39–16.5)
Tobacco use
No 90 (64.3) 428 (75.5) 0.102 1 1
Yes 50 (35.7) 139 (24.5) 1.50 (0.92–2.45) 1.65 (0.97–2.81)
*Adjusted for age, sex and year of diagnosis.
{{Association evaluated by Fisher’s Exact Test.
Data might not add up to totals due to missing values.
doi:10.1371/journal.pone.0027610.t002
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However, a direct causal relationship is far from being established.
Some evidence suggests that anemia may not at all be a risk factor
for the appearance of adverse effects, but rather the adverse
reaction itself [12,16,19]. Isoniazid and rifampicin may directly
cause hemolytic anemia, as can pyrazinamide cause sideroblastic
anemia [15]. Others have suggested that anemia is seen as part of
the clinical manifestation of tuberculosis and as a consequence of a
chronic disease (chronic disease induced anemia) [14]. In general,
tuberculosis patients have a higher predisposition to develop
gastrointestinal absorption problems, consequently leading to
anemia as a secondary side effect—yet not a risk factor itself
[14]. In addition, a selection bias might have occurred due to the
nutritionist selection of anemic cases. Thus, further studies are
needed in order to confirm and clarify these findings.
On the other hand, a body mass index more than 25 kg/m
2
(overweight and obesity) was also associated with adverse
reactions. Limited information is available regarding this associ-
ation, but a prior investigation reported that drug toxicity might
result in obese patients receiving total body weight doses [20].
Another study has overall reported that obesity can have some
effects on drug metabolism which could increase possibility of
adverse events [21]. Of notice, a BMI,18.5 kg/m
2, reported as a
risk factor for active TB [22,23,24], was not associated with
adverse reactions in our multivariable model as previously describe
in other papers [13,18].
Drugs associated with MDR-TB treatment is one of the most
important factors associated with adverse reactions, increasing risk
around 11 times compared to those who received first-line
therapy. A prior study involving MDR-TB patients in Peru
reported that 95% of treated patients had a type of adverse
reaction to second-line TB drugs, with a proportion of 54% as
toxic reactions [25]. Others studies have found high prevalences
(more than 50%) of adverse drug reactions among MDR-TB
patients [26,27] compared to the expected prevalence of mild
reactions in those using first-line therapy (around 5–20%) [19]. In
general, drugs for treating MDR-TB strains have greater toxicity
effects and involve a long-term exposure (18 to 24 months), all in
great contrast with the treatment of a sensitive strain of TB [28].
Finally, smoking was the last independent factor associated with
TB-drug adverse reactions. A previous case-control study found a
statistically significant association between smoking and liver
toxicity due to pyrazinamide [29]. However, literature regarding
this finding is limited and further studies are needed to corroborate
results.
Our study also found that other variables could be associated
with adverse reactions from anti-TB drugs. Alcohol use can
predispose and accelerate hepatotoxic effects caused especially by
isoniazid [30,31] due to enzyme induction changes [13]. Drug use
can also be associated with hepatotoxicity. Overall, drugs have
several effects which might affect the liver’s enzyme induction as
well as predisposing to hepatitis infection especially among
intravenous drug users [32,33]. Co-infection with hepatitis B or
C has proven to be a high risk for adverse drug effects [33].
Unfortunately, our study did not assess hepatitis B or C infection
as previously described. Surprisingly, HIV infection was not an
independent factor associated with drug reactions. Previous
authors have reported that side effects are higher in HIV-positive
than in HIV-negative patients [7,34], especially due to parallel
treatment with highly-active antiretroviral therapy (HAART)
[35,36]. In our context, a strong association between HIV
infection and MDR-TB (data not shown) might explain why
HIV infection is not part of the final multivariable model.
Surprisingly, diabetes—an expected risk factor [37]—was not a
risk factor for adverse events in this study.
Strengths of this study include the analysis of a reasonable
number of cases including only patients with adverse drug
reactions systematically reported by the National Health
Strategy for Control and Prevention of Tuberculosis. However,
this study has several limitations. First, because of the
retrospective nature of our study, it is not possible to
demonstrate a causal relationship between the variables. It
was not possible to determine the exact time of hemoglobin
assessment in relation to the appearance of adverse effects.
Moreover, some selection bias could have been introduced since
subjective nutritionist criteria was used to dose for hemoglobin
levels. Besides, missing data might have affected our results.
Nevertheless, our findings are similar to previous reports. Thus,
we believe that effect of missing value was not important in our
analysis. Second, we could not adjust our results for other well-
recognized confounders (education level or economic status).
Further studies are needed to corroborate our findings. This
study was not meant to assess the specific drug involved in the
adverse reaction. Finally, we could not assess the drug involved
in the reaction as previous reports have performed. However,
our primary interest was to find risk factors associated with the
occurrence of anti-TB adverse drug reactions.
In conclusion, older age, anemia, drugs associated with MDR-
TB treatment, overweight/obesity status, and smoking history are
in risk to develop anti-tuberculosis adverse drug reactions. Alcohol
use, drug consumption and HIV infection were also associated in
our age- and sex-adjusted models. Patients with these risk factors
should be carefully monitored during the anti-tuberculosis drug
treatment (DOTS strategy). A comprehensive clinical history
(smoking and body mass index) and additional exams, including
hemoglobin, hematocrit, HIV-ELISA, might be useful to identify
these patients.
Table 3. Multivariable Model of Independent Factors
Associated with TB-Treatment Adverse Effects.
Variables Multivariable model
OR (IC95%)
Age
,20 years 1
20–39 years 2.61 (1.17–5.79)
40 or more years 3.93 (1.65–9.35)
Anemia
No 1
Yes 2.10 (1.13–3.92)
Body Mass Index
Normal 1
BMI$25 kg/m
2 2.13 (1.17–3.89)
BMI,18.5 kg/m
2 0.87 (0.36–2.14)
MDR-TB
No 1
Yes 11.1 (6.29–19.6)
Tobacco Use
No 1
Yes 2.00 (1.03–3.87)
doi:10.1371/journal.pone.0027610.t003
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